These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Action of a novel anti-inflammatory agent: 804 CB on Masugi type experimental glomerulonephritis]. Vindel JA; Richer G; Khoury B; Hirbec G Arzneimittelforschung; 1974 Sep; 24(9A SUPPL):1378-84. PubMed ID: 4480067 [No Abstract] [Full Text] [Related]
44. [Clinical tolerance of kanendomycin in otorhinolaryngology]. Barberi G G Ital Chemioter; 1977; 24(1-2):15-6. PubMed ID: 615757 [No Abstract] [Full Text] [Related]
45. [Results of clinical trials of calcium bucloxate (804 CB) in rheumatology]. de Sèze S; Dryll A; Dreiser R Arzneimittelforschung; 1974 Sep; 24(9A SUPPL):1425-8. PubMed ID: 4614819 [No Abstract] [Full Text] [Related]
46. [Clinical evaluation of a new oral cephalosporin (cephalexin pivaloxymethyl ester) in pediatric otorhinolaryngology]. Magri M Clin Ter; 1976 Sep; 78(5):421-34. PubMed ID: 795598 [No Abstract] [Full Text] [Related]
47. [Kymalzone in current O.R.L. practice in children]. Danon J Ann Otolaryngol Chir Cervicofac; 1980 Dec; 97(12):1065-72. PubMed ID: 7018344 [No Abstract] [Full Text] [Related]
48. [Double-blind controlled research on symptomatic effects of an antibiotic-antiphlogistic combination in otorhinolaryngologic infections]. Occhiuzzi L Otorinolaringol Ital; 1972; 39(1):51-62. PubMed ID: 4550012 [No Abstract] [Full Text] [Related]
49. [The results of clinical observations and experimental research of some preparations produced by the pharmaceutic industry plant "Polfa" (author's transl)]. Semczuk B Ann Univ Mariae Curie Sklodowska Med; 1979; 34():291-6. PubMed ID: 400433 [No Abstract] [Full Text] [Related]
50. [Value of benzidamine in O.R.L]. Mounier-Kuhn P; Haguenauer JP; Bouchayer M J Fr Otorhinolaryngol Audiophonol Chir Maxillofac (1967); 1968 Feb; 17(2):143. PubMed ID: 4249518 [No Abstract] [Full Text] [Related]
51. [Clinical use of azidocillin in pediatrics. Evaluation of the clinical effectiveness and tolerance in respiratory and otorhinolaryngologic infections]. Barbato G; Cavalieri S; Salerno A Minerva Pediatr; 1982 May; 34(10):469-74. PubMed ID: 6897099 [No Abstract] [Full Text] [Related]
53. [Contribution to the study of anti-inflammatory agents in the surgical, stomatologic and ENT sequelae]. Toucas P Rev Fr Odontostomatol; 1966; 13(7):1218-30. PubMed ID: 5225240 [No Abstract] [Full Text] [Related]
54. [Remarks and results obtained with an antiphlogistic and analgesic preparation in otorhinolaryngology]. Girardi G Minerva Otorinolaringol; 1967; 17(5):115-8. PubMed ID: 5611123 [No Abstract] [Full Text] [Related]
56. [Clinical experiences with Voltaren a new nonsteroid antirheumatic agent]. Ciccolunghi SN; Levi B; Chaudri HA Wien Med Wochenschr; 1975 Jan; 125(4):66-70. PubMed ID: 1093333 [No Abstract] [Full Text] [Related]
57. [Experimentation with a new semisynthetic molecule (Dexacillin) in otorhinolaryngology]. Decroix G Lille Med; 1975 Jan; 20(1):51-2. PubMed ID: 1134172 [No Abstract] [Full Text] [Related]
59. [Symptomatic treatment of allergies and seasonal infections of the field of otorhinolaryngology]. Bourguet J; Du Plessis De Grenedan Y; Dumeyniou P Ann Otolaryngol Chir Cervicofac; 1974; 91(10-11):633-8. PubMed ID: 4469758 [No Abstract] [Full Text] [Related]
60. [Hexahydropyrazine salt of phenylbutazone in O.R.L]. Laccourreye H Ann Otolaryngol Chir Cervicofac; 1970 Jun; 87(6):397-402. PubMed ID: 5424469 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]